Astellas Pharma U.S. of Deerfield, IL, last week touted study results that show its Lexiscan pharmacologic stress agent for myocardial perfusion imaging (MPI) is safe and comparable to the current standard agent, Adenoscan, the company said.
Lexiscan requires infrequent use of aminophylline to reverse its effect in case of adverse events, according to a study conducted by researchers at the Cleveland Clinic and presented at the American Society of Nuclear Cardiology (ASNC) meeting in Minneapolis. The researchers compared patient characteristics, side effects, and aminophylline treatment timing and dosage for 2,015 patients randomized to Lexiscan (1337) or Adenoscan (678).
Results showed that aminophylline was given to 46 Lexiscan patients and 12 Adenoscan patients. Although aminophylline use was slightly higher for patients randomized to Lexiscan, no specific adverse event occurred significantly more often with Lexiscan than with Adenoscan, Astellas said.
Related Reading
Astellas releases Lexiscan stress agent, June 30, 2008
Heart-imaging agent gets FDA approval, April 14, 2008
Copyright © 2009 AuntMinnie.com
